The DOI matches its Crossref record; 27 of the 29 references it cites were found in a registry or an index.
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Abstract
Background Nanoliposomal irinotecan showed activity in a phase 2 study in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapies. We assessed the effect of nanoliposomal irinotecan alone or combined with fluorouracil and folinic acid in a phase 3 trial in this population.Methods We did a global, phase 3, randomised, open-label trial at 76 sites in 14 countries. Eligible patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy were randomly assigned (1:1) using an interactive web response system at a central location to receive either nanoliposomal irinotecan monotherapy (120 mg/m(2) every 3 weeks, equivalent to 100 mg/m(2) of irinotecan base) or fluorouracil and folinic acid. A third arm consisting of nanoliposomal irinotecan (80 mg/m(2), equivalent to 70 mg/m(2) of irinotecan base) with fluorouracil and folinic acid every 2 weeks was added later (1:1:1), in a protocol amendment. Randomisation was stratified by baseline albumin, Karnofsky performance status, and ethnic origin. Treatment was continued until disease progression or intolerable toxic effects. The primary endpoint was overall survival, assessed in the intention-to-treat population. The primary analysis was planned after 305 events. Safety was assessed in all patients who had received study drug. This trial is registered at ClinicalTrials.gov, number NCT01494506.Findings Between Jan 11, 2012, and Sept 11, 2013, 417 patients were randomly assigned either nanoliposomal irinotecan plus fluorouracil and folinic acid (n=117), nanoliposomal irinotecan monotherapy (n=151), or fluorouracil and folinic acid (n=149). After 313 events, median overall survival in patients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid was 6.1 months (95% CI 4.8-8.9) vs 4.2 months (3.3-5.3) with fluorouracil and folinic acid (hazard ratio 0.67, 95% CI 0.49-0.92; p=0.012). Median overall survival did not differ between patients assigned nanoliposomal irinotecan monotherapy and those allocated fluorouracil and folinic acid (4.9 months [4.2-5.6] vs 4.2 months [3.6-4.9]; 0.99, 0.77-1.28; p=0.94). The grade 3 or 4 adverse events that occurred most frequently in the 117 patients assigned nanoliposomal irinotecan plus fluorouracil and folinic acid were neutropenia (32 [27%]), diarrhoea (15 [13%]), vomiting (13 [11%]), and fatigue (16 [14%]).Interpretation Nanoliposomal irinotecan in combination with fluorouracil and folinic acid extends survival with a manageable safety profile in patients with metastatic pancreatic ductal adenocarcinoma who previously received gemcitabine-based therapy. This agent represents a new treatment option for this population.Funding Merrimack Pharmaceuticals.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients progressing on first-line regimens can be offered the possibility of switching to the other regimen, or a second-line regimen that includes a liposomal formulation of irinotecan in combination with 5-FU10, provided they have not received either of these agents previously.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [10]
Citations
Cites
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Self-citationIncreased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationBurris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P. G., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,895
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Oettle, H., Riess, H. B., Stieler, J., Heil, G., Schwaner, I., Seraphin, J., Görner, M., Mölle, M., Greten, T. F., Lakner, V., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6995 · Cited by 492
Self-citationKalra, A. V., Kim, J., Klinz, S. G., Paz, N., Cain, J. E., Drummond, D. C., Nielsen, U. B., & Fitzgerald, J. B. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0572 · Cited by 199
Self-citationPharmacogenetics of irinotecan metabolism and transport: An update
Smith, N. F., Figg, W. D., & Sparreboom, A. (2005) · Toxicology in Vitro · doi:10.1016/j.tiv.2005.06.045 · Cited by 190
Yoo, C., Hwang, J. Y., Kim, J. H., Kim, T. W., Lee, J. S., Park, D. H., Lee, S. K., Seo, D. W., Lee, S. S., Kim, M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605374 · Cited by 169
Self-citationKo, A. H., Tempero, M. A., Shan, Y.-S., Su, W., Lin, Y.-L., Dito, E., Ong, A., Wang, Y.-W., Yeh, C. G., & Chen, L.-T. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.408 · Cited by 160
Self-citationRoy, A. C., Park, S. R., Cunningham, D., Kang, Y., Chao, Y., Chen, L., Rees, C., Lim, H. Y., Tabernero, J. M., Ramos, F. J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt002 · Cited by 123
Self-citation
Cited by
Sorted by citations
Items 301–400 of 1,000
Hashimoto, D., Satoi, S., Fujii, T., Sho, M., He, J. P., Hackert, T., Chiaro, M. D., Jang, J., Gulla, A., Yoon, Y., et al. (2023) · Pancreatology · doi:10.1016/j.pan.2023.07.005 · Cited by 29
Self-citationOhba, A., Ozaka, M., Mizusawa, J., Okusaka, T., Kobayashi, S., Yamashita, T., Ikeda, M., Yasuda, I., Sugimori, K., Sasahira, N., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco.24.00936 · Cited by 29
Geddie, M. L., Kohli, N., Kirpotin, D. B., Razlog, M., Jiao, Y., Kornaga, T., Rennard, R., Xu, L., Schoerberl, B., Marks, J. D., et al. (2016) · mAbs · doi:10.1080/19420862.2016.1259047 · Cited by 29
Pelzer, U., Blanc, J.-F., Melisi, D., Cubillo, A., Von Hoff, D. D., Wang-Gillam, A., Chen, L.-T., Siveke, J. T., Wan, Y., Solem, C. T., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.67 · Cited by 26
“All rights reserved 0007 – 0920/17 FULL PAPER Keywords: Q-TWiST; metastatic pancreatic cancer; clinical trial; NAPOLI-1 British Journal of Cancer (2017) 116, 1247–1253 | doi: 10.1038/bjc.2017.67 www.bjcancer.com | DOI:10.1038/bjc.2017.67 1247 Pancreatic cancer remains one of the most fatal and least understood human m…”
BackgroundMethodInfluentialSelf-citationMulticenter phase II trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic cancer
Chung, M. J., Kang, H., Kim, H. G., Hyun, J. J., Lee, J. K., Lee, K. H., Noh, M. H., Kang, D. H., Lee, S. H., & Bang, S. (2018) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v10.i12.505 · Cited by 29
Self-citationOhkuma, R., Yada, E., Ishikawa, S., Komura, D., Ishizaki, H., Tamada, K., Kubota, Y., Hamada, K., Ishida, H., Hirasawa, Y., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0226707 · Cited by 31
Merz, V., Zecchetto, C., Santoro, R., Simionato, F., Sabbadini, F., Mangiameli, D., Piro, G., Cavaliere, A., Deiana, M., Valenti, M. T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0395 · Cited by 29
“No randomized phase III trials explored standard irinotecan-containing regimens in this setting (21, 22) To date, NAPOLI-1 remains the largest phase III study in second-line metastatic pancreatic cancer (12).”
BackgroundLee, J.-C., Woo, S. M., Shin, D. W., Kim, J., Yang, S. Y., Kim, M. J., Kim, J. W., Kim, J., Lee, W. J., Cha, H. S., et al. (2020) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000730 · Cited by 29
Self-citationPrager, G. W., Oehler, L., Gerger, A., Mlineritsch, B., Andel, J., Petzer, A. L., Wilthoner, K., Sliwa, T., Pichler, P., Winder, T. L., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.003 · Cited by 29
Hendifar, A. E., Blais, E. M., Wolpin, B. M., Subbiah, V., Collisson, E. A., Singh, I., Cannon, T. L., Shaw, K. R. M., Petricoin, E. F., Klempner, S. J., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00494 · Cited by 31
“0/I (IPMN) 4/81 (5) 0/52 (0) 0/16 (0) 0/36 (0)”
Self-citationMetronomic Anti-Cancer Therapy: A Multimodal Therapy Governed by the Tumor Microenvironment
Muñoz, R., Girotti, A., Hileeto, D., & Arias, F. J. (2021) · Cancers · doi:10.3390/cancers13215414 · Cited by 31
Umemoto, K., Yamamoto, H., Oikawa, R., Takeda, H., Doi, A., Horie, Y., Arai, H., Ogura, T., Mizukami, T., Izawa, N., et al. (2022) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djac106 · Cited by 27
Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma
Huffman, B. M., Ellis, H., Jordan, A. C., Freed-Pastor, W. A., Perez, K. J., Rubinson, D. A., Sethi, N. S., Singh, H., Surana, R., Wolpin, B. M., et al. (2022) · Cancers · doi:10.3390/cancers14246223 · Cited by 31
“5 months), and the ORR (16% versus 1%) [22].”
BackgroundChen, L., Siveke, J. T., Wang‐Gillam, A., Li, C., Bodoky, G., Dean, A. P., Shan, Y., Jameson, G., Macarulla, T. M., Lee, K.-H., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.010 · Cited by 29
Self-citationGlobal regulations and legislations on nanoparticles usage and application in diverse horizons
Mishra, A. K., Das, R., Sahoo, S., & Biswal, B. (2022) · Comprehensive analytical chemistry · doi:10.1016/bs.coac.2021.12.004 · Cited by 30
Shin, S., Park, C. M., Kwon, H., & Lee, K.-H. (2016) · BMC Cancer · doi:10.1186/s12885-016-2482-z · Cited by 28
Self-citationAdvancements in Nanomedicine for Multiple Myeloma
Detappe, A., Bustoros, M. W., Mouhieddine, T. H., & Ghoroghchian, P. P. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.04.005 · Cited by 27
Deneka, A. Y., Boumber, Y., Beck, T. N., & Golemis, E. A. (2019) · Cancers · doi:10.3390/cancers11091297 · Cited by 28
“Onivyde is a nanoliposome conjugated with irinotecan for pancreatic cancer management [152].”
BackgroundGreene, M. K., Nogueira, J. C. F., Tracey, S. R., Richards, D. A., McDaid, W. J., Burrows, J. F., Campbell, K., Longley, D. B., Chudasama, V., & Scott, C. J. (2020) · Nanoscale · doi:10.1039/d0nr02387f · Cited by 28
Self-citationMu, L., Song, Y., Zhao, K., Liu, Y., Fan, Q., Wang, X., Li, Q., Wang, X., & Huang, J. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13913 · Cited by 27
Go, S., Lee, S., Bae, W. K., Zang, D. Y., Lee, H. W., Jang, J. S., Ji, J. H., Kim, J. H., Park, S.-G., Sym, S. J., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.002 · Cited by 28
Self-citationIoka, T., Ueno, M., Ueno, H., Park, J. O., Chang, H.-M., Sasahira, N., Kanai, M., Chung, I. J., Ikeda, M., Nakamori, S., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.004 · Cited by 28
Self-citationPharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges
Diab, M., Azmi, A. S., Mohammad, R. M., & Philip, P. A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1561869 · Cited by 28
“NAPOLI-1 trial, 417 patients with metastatic PDAC previously treated with a GEM-based regimen were randomized to single-agent LI, LI with 5-FU/leucovorin, or 5-FU/leucovorin alone [87].”
MethodGurreri, E., Genovese, G., Perelli, L., Agostini, A., Piro, G., Carbone, C., & Tortora, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119313 · Cited by 27
Camptothein-Based Anti-Cancer Therapies and Strategies to Improve Their Therapeutic Index
Gong, J., Zhang, W., & Balthasar, J. P. (2025) · Cancers · doi:10.3390/cancers17061032 · Cited by 28
Kawaguchi, K., Igarashi, K., Miyake, K., Lwin, T. M., Miyake, M., Kiyuna, T., Hwang, H. K., Murakami, T., DeLong, J. C., Singh, S. R., et al. (2018) · Tissue and Cell · doi:10.1016/j.tice.2018.05.003 · Cited by 28
Nanocarriers in Different Preclinical and Clinical Stages
Abed, S. N., Deb, P. K., Surchi, H. S., Kokaz, S. F., Jamal, S. M., Bandopadhyay, S., & Tekade, R. K. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817909-3.00017-0 · Cited by 30
Tramontano, A. C., Chen, Y., Watson, T. R., Eckel, A. L., Sheehan, D. F., Peters, M. L. B., Pandharipande, P. V., Hur, C., & Kong, C. Y. (2019) · Medicine · doi:10.1097/md.0000000000018082 · Cited by 27
Self-citationWeinberg, B. A., Wang, H., Witkiewicz, A. K., Marshall, J. L., He, A. R., Vail, P. J., Knudsen, E. S., & Pishvaian, M. J. (2020) · Journal of Pancreatic Cancer · doi:10.1089/pancan.2020.0005 · Cited by 27
Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma
Rebelo, R., Polónia, B. R. G., Santos, L. L., Vasconcelos, M. H., & Xavier, C. P. R. (2021) · Pharmaceuticals · doi:10.3390/ph14030280 · Cited by 30
Kasi, A., McGinnis, T., Naik, G., Handa, S., Williams, G. R., & Paluri, R. K. (2021) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-20-338 · Cited by 27
“In 2015, the National Cancer Care Network (NCCN) guidelines adapted nal-IRI + 5-FU/LV as a 2 line therapy, post-failure of gemcitabine-inclusive regimens for advanced PAC, based on NAPOLI-1 trial (9).”
BackgroundMethodResultInfluentialSeufferlein, T. T. W., Mayerle, J. V., Böck, S., Brunner, T. B., Ettrich, T. J., Grenacher, L., Gress, T. M., Hackert, T., Heinemann, V., Kestler, A. M. R., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1856-7346 · Cited by 29
Self-citationAre targeted therapies or immunotherapies effective in metastatic pancreatic adenocarcinoma?
Rémond, M., Pellat, A., Brézault, C., Dhooge, M., & Coriat, R. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100638 · Cited by 28
Rehman, S. S. U., Lim, K., & Wang‐Gillam, A. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1174581 · Cited by 27
Self-citationIoka, T., Komatsu, Y., Mizuno, N., Tsuji, A., Ohkawa, S., Tanaka, M., Iguchi, H., Ishiguro, A., Kitano, M., Satoh, T., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.436 · Cited by 27
“…folinic acid, and FU, 2.9 months; folinic acid and FU, 2.0 months; Oettle et al, 2014), the PANCREOX study (mFOLFOX, 3.1 months; FU/leucovorin (LV), 2.9 months; Gill et al, 2016), and the NAPOLI-1 study (5- FU/LV/nanoliposomal irinotecan, 3.1 months; FU/LV, 1.5 months; Wang-Gillam et al, 2016).”
BackgroundResultInfluentialMatera, R. M., & Saif, M. W. (2017) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1362388 · Cited by 27
“The approval of nab-paclitaxel and nanoliposomal irinotecan not only added much needed treatment options; it also confirmed the plausibly of augmenting the efficacy of traditional chemotherapeutic agents though the use of new technology such as nanoformulation and conjugation [17].”
BackgroundSmall molecule tyrosine kinase inhibitors and pancreatic cancer—Trials and troubles
Bhaskar, L. V., Farran, B., Lakkakula, S., Peela, S., Yarla, N. S., Bramhachari, P. V., Kamal, M. A., Saddala, M. S., & Nagaraju, G. P. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.09.011 · Cited by 26
Pancreatic Cancer: Pathogenesis and Clinical Studies
Zhou, K., Liu, Y., Tang, C., & Zhu, H. (2025) · MedComm · doi:10.1002/mco2.70162 · Cited by 28
Macarulla, T. M., Blanc, J., Wang‐Gillam, A., Chen, L., Siveke, J. T., Mirakhur, B., Chen, J., & de Jong, F. A. (2019) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.02.011 · Cited by 26
Self-citationNanomedicine Strategies to Enhance Tumor Drug Penetration in Pancreatic Cancer
Lu, T., & Prakash, J. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s279192 · Cited by 27
Heumann, T. R., & Azad, N. S. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09981-3 · Cited by 26
Park, S. J., Kim, H., Shin, K., Hong, T. H., Suh, J. H., & Lee, M. A. (2021) · BMC Cancer · doi:10.1186/s12885-021-08887-1 · Cited by 26
Slapak, E. J., el Mandili, M., Bijlsma, M. F., & Spek, C. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020390 · Cited by 27
McNamara, M. G., Swain, J., Craig, Z., Sharma, R., Faluyi, O. O., Wadsley, J., Morgan, C., Wall, L. R., Chau, I., Reed, N., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102015 · Cited by 26
Self-citationWoo, W., Carey, E. T., & Choi, M. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s167590 · Cited by 26
“nal-IRI/5-FU/LV and 26% of those who receiving 5-FU/LV had this side effect.(19) These findings are similar to phase I and phase II trials of nal-IRI.”
BackgroundResultInfluentialHuffman, B. M., Basu Mallick, A., Horick, N. K., Wang-Gillam, A., Hosein, P. J., Morse, M. A., Beg, M. S., Murphy, J. E., Mavroukakis, S., Zaki, A., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.49720 · Cited by 25
Self-citationLiposomal therapies in oncology: does one size fit all?
Sousa, I., Rodrigues, F., Prazeres, H., Lima, R. T., & Soares, P. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3668-7 · Cited by 25
Petrillo, A., Pappalardo, A., Calabrese, F., Tirino, G., Pompella, L., Ventriglia, J., Laterza, M. M., Caterino, M., Sforza, V., Iranzo, V., et al. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.06.02 · Cited by 25
Pijnappel, E. N., Dijksterhuis, W. P. M., van der Geest, L. G., de Vos‐Geelen, J., de Groot, J. W. B., Homs, M. Y. V., Creemers, G., Mohammad, N. H., Besselink, M. G., van Laarhoven, H. W. M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7028 · Cited by 25
Ou, K., Liu, X., Li, W., Yang, Y., Ying, J., & Yang, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.724815 · Cited by 25
Committee of the Korean clinical practice guideline for pancreatic cancer and National Cancer Center, K. (2021) · Pancreatology · doi:10.1016/j.pan.2021.05.004 · Cited by 27
Hamada, T., Nakai, Y., Isayama, H., Yasunaga, H., Matsui, H., Takahara, N., Mizuno, S., Kogure, H., Matsubara, S., Yamamoto, N., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.05.016 · Cited by 25
Bernards, N., Ventura, M., Fricke, I. B., Hendriks, B. S., Fitzgerald, J. B., Lee, H., & Zheng, J. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00540 · Cited by 25
Pancreatic cancer: New hopes after first line treatment
Aroldi, F., Bertocchi, P., Savelli, G., Rosso, E., & Zaniboni, A. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i9.682 · Cited by 24
Kim, A. Y., Frantz, S. K., Brower, J. S., & Akhter, N. M. (2019) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2018.09.020 · Cited by 24
Palliative chemotherapy in pancreatic cancer—treatment sequences
Abbassi, R., & Algül, H. (2019) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.06.09 · Cited by 25
“The use of trametinib together with chloroquine for example led to a decrease of the CA 19-9 Table 3 Key trials for palliative chemotherapy in pancreatic cancer (1,2,4,5,12,15-17)”
BackgroundAdvances in the management of pancreatic ductal adenocarcinoma
O'Kane, G. M., Ladak, F., & Gallinger, S. (2021) · Canadian Medical Association Journal · doi:10.1503/cmaj.201450 · Cited by 23
Ayasun, R., Saridogan, T., Gaber, O., & Şahin, İ. H. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.11.001 · Cited by 22
Zhong, Z.-X., Li, X., Liu, J., Qin, N., Duan, H., & Duan, X.-C. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s404848 · Cited by 24
Chiang, N., Chang, J., Shan, Y., & Chen, L. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1183646 · Cited by 24
“6) failed to demonstrate its superiority over the 5-FU/LV arm.[31] The hazard ratio of the OS”
BackgroundMethodInfluentialSelf-citationRecent advances in the management of pancreatic adenocarcinoma
Karakaş, Y., Laçin, Ş., & Yalçın, Ş. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1403319 · Cited by 24
“The efficacy of liposomal irinotecan combined with 5-FU and folinic acid has been assessed in the phase III NAPOLI-1 trial [69].”
BackgroundSeek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles
Rodallec, A., Fanciullino, R., Lacarelle, B., & Ciccolini, J. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1477586 · Cited by 24
“This led to requiring 25% reduction in dosing during further registration trials in patients with unfavorable UGT1A1 status [77].”
BackgroundInfluentialReflections on depletion of tumor stroma in pancreatic cancer
Wang, W.-Q., Liu, L., Xu, J.-Z., & Yu, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.01.007 · Cited by 24
Tossey, J., Reardon, J., VanDeusen, J. B., Noonan, A. M., Porter, K. M., & Arango, M. J. (2019) · Medical Oncology · doi:10.1007/s12032-019-1309-6 · Cited by 24
“This approval was based on the results of the NAPOLI-1 trial, a multinational phase III study that demonstrated improved survival for patients treated with naliri/5FU as compared to those treated with 5FU alone [6].”
The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan
Su, Y., Chiang, N.-J., Chang, J. S., Wang, Y.-W., Shen, B.-N., Li, Y.-J., Hwang, D. Y., Shan, Y., & Chen, L. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100746 · Cited by 23
“In the NAPOLI-1 study, the incidence of grade 3 diarrhea was closely associated with tIRICmax, and both were higher in the Caucasian (versus Asian) population and in patients receiving higher dose of nal-IRI (120 mg/m(2) as monotherapy versus 80 mg/m(2) plus 5-FU/LV).(1,13,19) Interestingly, the association between gr…”
BackgroundSelf-citationRecent advancements in nanoparticles for cancer treatment
Sharma, D. K. (2025) · Medical Oncology · doi:10.1007/s12032-025-02609-4 · Cited by 24
“Steric stabilization is made possible by PEG or other compounds, which also inhibit protein adsorption, particle interactions, and interactions with immune cells [124].”
Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib
Banno, E., Togashi, Y., Velasco, M. A. D., Mizukami, T., Nakamura, Y., Terashima, M., Sakai, K., Fujita, Y., Kamata, K., Kitano, M., et al. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.3961 · Cited by 23
WAVE3 promotes proliferation, migration and invasion via the AKT pathway in pancreatic cancer
Huang, S., Huang, C., Chen, W., Liu, Y., Yin, X., Lai, J., Liang, L., Wang, Q., Wang, A., & Zheng, C. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4421 · Cited by 23
Chiasakul, T., Patell, R. D., Maraveyas, A., Carrier, M., & Zwicker, J. I. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15175 · Cited by 23
“Wang-Gillam et al 2016 [33] Metastatic pancreatic cancer previously treated with gemcitabine Second line 398 Nanoliposomal irinotecan OR Nanoliposomal irinotecan + 5-Flurouracil + folinic acid 5-Flurouracil + folinic acid Overall survival Not done 100 NR 4.”
BackgroundInfluentialGuidelines for the diagnosis and treatment of pancreatic cancer in China (2021)
Yang, Y., Bai, X., Bian, D., Cai, S., Chen, R., Cao, F., Dai, M., Fang, C., Fu, D., Ge, C., et al. (2021) · Journal of Pancreatology · doi:10.1097/jp9.0000000000000072 · Cited by 23
“For patients with good physical status, Nanoliposomal irinotecan combined with fluorouracil and folinic acid,([62,63]) or oxaliplatin with fluorouracil/folinic acid is recommended.”
BackgroundSu, Y., Chiu, Y., Li, C., Yang, S., Lin, J., Lin, S., Chang, P., Chiang, N., Shan, Y., Ch’ang, H.-J., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01649-7 · Cited by 23
“6 versus 25% in T1204, due to the approval of national health insurance reimbursement for oral S-1 in June 2014 and nal-IRI+ 5-FU/LV in August 2018 [20, 21].”
BackgroundSelf-citationConte, M., & Cauda, V. (2022) · Advanced Therapeutics · doi:10.1002/adtp.202200079 · Cited by 27
A recent update on therapeutic potential of vesicular system against fungal keratitis
Sanap, S. N., Kedar, A. S., Bisen, A. C., Agrawal, S., & Bhatta, R. S. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103721 · Cited by 24
Prognosis of Pancreatic Cancer Based on Resectability: A Single Center Experience
Einama, T., Takihata, Y., Aosasa, S., Konno, F., Kobayashi, K., Yonamine, N., Fujinuma, I., Tsunenari, T., Nakazawa, A., Shinto, E., et al. (2023) · Cancers · doi:10.3390/cancers15041101 · Cited by 23
A Phase II Study of Ganetespib as Second-line or Third-line Therapy for Metastatic Pancreatic Cancer
Cardin, D. B., Thota, R., Goff, L. W., Berlin, J. D., Jones, C. M., Ayers, G. D., Whisenant, J. G., & Chan, E. W. (2017) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000377 · Cited by 23
“0 3 1 11 Line of therapy for unresectable disease 1st 8 2nd 6 Median CA 19-9 levels at baseline (range) 5672 (1-49402)”
BackgroundNakagawa, K., Akahori, T., Nishiwada, S., Nagai, M., Nakamura, K., Tanaka, T., Tamamoto, T., Ohbayashi, C., Hasegawa, M., Kichikawa, K., et al. (2018) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-018-1709-7 · Cited by 23
Seghers, A.-K., Cuyle, P.-J. A., & Cutsem, E. V. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00727-9 · Cited by 22
Real World Evidence on Second-Line Palliative Chemotherapy in Advanced Pancreatic Cancer
Gränsmark, E., Bylin, N. B., Blomstrand, H., Fredrikson, M. G., Åvall-Lundqvist, E. H., & Elander, N. O. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01176 · Cited by 23
“While many other studies fail to report TTF2, the TTF2measures reported in the randomized second-line NAPOLI-1 trial (5) were 1.”
BackgroundExtensive Review of Nanomedicine Strategies Targeting the Tumor Microenvironment in PDAC
Liu, X., Shao, Y., Li, Y., Chen, Z., Shi, T., Tong, Q., Zou, X., Ju, L., Pan, J., Zhuang, R., et al. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s504503 · Cited by 27
“26 However, compared with that of patients treated with a combination of 5-FU and leucovorin, the survival period of patients treated with irinotecan liposomes alone did not improve.”
Xie, N., Tian, C., Wu, H. M., Yang, X., Liu, L., Li, J., Xiao, H., Gao, J., Lü, J., Hu, X., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920915305 · Cited by 22
Chae, H., Jeong, H., Cheon, J., Chon, H. J., Ryu, H., Kim, I. H., Kang, M. J., Jeong, J. H., Ryoo, B., Kim, K., et al. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920923424 · Cited by 23
Recent Nanocarrier Approaches for Targeted Drug Delivery in Cancer Therapy
Bhatia, R., Sharma, A., Narang, R. K., & Rawal, R. K. (2020) · Current Molecular Pharmacology · doi:10.2174/1874467213666200730114943 · Cited by 22
Markus, M., Abendroth, A., Noureddine, R., Paul, A., Breitenbuecher, S., Virchow, I., Schmid, K. W., Markus, P. M., Schumacher, B. M., Wiesweg, M., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03361-0 · Cited by 22
Self-citationGermline Aberrations in Pancreatic Cancer: Implications for Clinical Care
Casolino, R., Corbo, V., Beer, P. A., Hwang, C., Paiella, S., Silvestri, V., Ottini, L., & Biankin, A. V. (2022) · Cancers · doi:10.3390/cancers14133239 · Cited by 24
Chun, J. W., Woo, S. M., Lee, S. H., Choi, J. H., Park, N., Kim, J. S., Cho, I. R., Paik, W. H., Lee, W. J., Ryu, J. K., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221119539 · Cited by 23
Self-citationDrug Stability and Minimized Acid-/Drug-Catalyzed Phospholipid Degradation in Liposomal Irinotecan
Kirpotin, D. B., Hayes, M. E., Noble, C. O., Huang, Z. R., Wani, K., Moore, D., Kesper, K., Brien, D. O., & Drummond, D. C. (2022) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.11.025 · Cited by 22
Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.
Lakatos, G., Petrányi, Á., Szűcs, A., Nehéz, L., Harsányi, L., Hegyi, P. J., & Bodoky, G. (2017) · Pathology & Oncology Research · doi:10.1007/s12253-016-0176-0 · Cited by 22
Self-citationKobayashi, N., Shimamura, T., Tokuhisa, M., Goto, A., Endo, I., & Ichikawa, Y. (2017) · Medicine · doi:10.1097/md.0000000000006769 · Cited by 22
Differences in Nanoparticle Uptake in Transplanted and Autochthonous Models of Pancreatic Cancer
Tao, Z., Muzumdar, M. D., Detappe, A., Huang, X., Xu, E. S., Yu, Y., Mouhieddine, T. H., Song, H., Jacks, T., & Ghoroghchian, P. P. (2018) · Nano Letters · doi:10.1021/acs.nanolett.7b04043 · Cited by 22
Ahn, D. H., Ramanathan, R. K., & Bekaii‐Saab, T. (2018) · Cancers · doi:10.3390/cancers10060193 · Cited by 22
Self-citationEverolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC)
Babiker, H. M., Karass, M., Recio‐Boiles, A., Chandana, S. R., McBride, A., & Mahadevan, D. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1632289 · Cited by 22
“patients, after progression on gemcitabine-based therapy [9].”
Perkhofer, L., Berger, A. W., Beutel, A. K., Gallmeier, E., Angermeier, S., von Weikersthal, L. F., Goetze, T. O., Muche, R., Seufferlein, T. T. W., & Ettrich, T. J. (2019) · BMC Cancer · doi:10.1186/s12885-019-6142-y · Cited by 22
Self-citationCurrent controversies and advances in the management of pancreatic adenocarcinoma
Zeeshan, M. S., & Ramzan, Z. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i6.472 · Cited by 22
Human pancreatic cancer progression: an anarchy among CCN-siblings
Banerjee, S. K., Maity, G., Haque, I., Ghosh, A., Sarkar, S., Gupta, V. G., Campbell, D. R., Hoff, D. D. V., & Banerjee, S. (2016) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-016-0343-9 · Cited by 21
Lao, M., Zhang, X., Ma, T., Xu, J., Yang, H., Duan, Y., Ying, H., Zhang, X., Guo, C., Qiu, J., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01763-z · Cited by 21
Diwakarla, C. S., Hannan, K. M., Hein, N., & Yip, D. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i13.2276 · Cited by 21
Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication
Hung, Y., Hsu, M., Chen, L., Hung, W., & Pan, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060903 · Cited by 22
Self-citationMesmar, F., Dai, B., Ibrahim, A. A., Hases, L., Jafferali, M. H., Augustine, J. J., DiLorenzo, S., Kang, Y., Zhao, Y., Wang, J., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2581 · Cited by 21
Musashi-1 promotes stress-induced tumor progression through recruitment of AGO2
Chen, H.-Y., Wang, M., Laurent, B., Hsu, C.-H., Chen, M.-T., Lin, L., Shen, J., Chang, W., Hsu, J. L., Hung, M., et al. (2019) · Theranostics · doi:10.7150/thno.35895 · Cited by 21
“GBM and PDAC are highly malignant tumors with dismal prognosis and a short survival time even after a completed treatment [28, 29].”
BackgroundSelf-citationGower, A., Golestany, B., Gong, J., Singhi, A. D., & Hendifar, A. E. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00365 · Cited by 23
Metadata
- Authors
- Wang-Gillam, A., Li, C.-P., Bodoky, G., Dean, A., Shan, Y.-S., Jameson, G., Macarulla, T., Lee, K.-H., Cunningham, D., Blanc, J. F., Hubner, R. A., Chiu, C.-F., Schwartsmann, G., Siveke, J. T., Braiteh, F., Moyo, V., Belanger, B., Dhindsa, N., Bayever, E., Von Hoff, D. D., Chen, L.-T., Adoo, C., Anderson, T., Asselah, J., Azambuja, A., Bampton, C., Barrios, C. H., Bekaii-Saab, T., Bohuslav, M., Chang, D., Chen, J.-S., Chen, Y.-C., Choi, H. J., Chung, I. J., Chung, V., Csoszi, T., Cubillo, A., DeMarco, L., de Wit, M., Dragovich, T., Edenfield, W., Fein, L. E., Franke, F., Fuchs, M., Gonzales-Cruz, V., Gozza, A., Fernando, R. H., Iaffaioli, R., Jakesova, J., Kahan, Z., Karimi, M., Kim, J. S., Korbenfeld, E., Lang, I., Lee, F.-C., Lee, K.-D., Lipton, L., Ma, W. W., Mangel, L., Mena, R., Palmer, D., Pant, S., Park, J. O., Piacentini, P., Pelzer, U., Plazas, J. G., Prasad, C., Rau, K.-M., Raoul, J.-L., Richards, D., Ross, P., Schlittler, L., Smakal, M., Stahalova, V., Sternberg, C., Seufferlein, T., Tebbutt, N., Vinholes, J. J., Wadlow, R., Wenczl, M., & Wong, M.
- Affiliations
- Taipei Veterans General Hospital (TW)
- St John of God Subiaco Hospital (AU)
- National Cheng Kung University Hospital (TW)
- Translational Genomics Research Institute (US)
- Vall d'Hebron Institute of Oncology (ES)
- Seoul National University Hospital (KR)
- Royal Marsden Hospital (GB)
- Hôpital Saint-André (FR)
- The Christie NHS Foundation Trust (GB)
- China Medical University Hospital (TW)
- Hospital de Clínicas de Porto Alegre (BR)
- TUM Klinikum (DE)
- Comprehensive Cancer Centers of Nevada (US)
- Merrimack Pharmaceuticals (United States) (US)
- Kaohsiung Medical University (TW)
- Corresponding author
- Chen, Li-Tzong
- ORCID
- Li, Chung-Pin
- Dean, Andrew
- Shan, Yan-Shen
- Jameson, Gayle
- Macarulla, Teresa
- Lee, Kyung-Hun
- Cunningham, David
- Hubner, Richard A
- Schwartsmann, Gilberto
- Siveke, Jens T
- Braiteh, Fadi
- Moyo, Victor
- Belanger, Bruce
- Chen, Li-Tzong
- Asselah, Jamil
- Barrios, Carlos Henrique
- Chang, David
- Chen, Jen-Shi
- Chen, Yeu-Chin
- Choi, Hye Jin
- Chung, Vincent
- Cubillo, Antonio
- Dragovich, Tomislav
- Fein, Luis Enrique
- Fuchs, Martin
- Korbenfeld, Ernesto
- Lee, Fa-Chyi
- Lee, Kuan-Der
- Ma, Wen Wee
- Palmer, Daniel
- Pant, Shubham
- Park, Joon Oh
- Pelzer, Uwe
- Rau, Kun-Ming
- Raoul, Jean-Luc
- Richards, Donald
- Ross, Paul
- Stahalova, Vladimira
- Sternberg, Cora
- Seufferlein, Thomas
- Tebbutt, Niall
- Wadlow, Raymond
- Wong, Mark
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2016-02
- Volume
- 387
- Issue
- 10018
- Pages
- 545-557
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2187917981
- Cited by
- 1,222
- References
- 29
- Citations by year
- 2026: 92 · 2025: 123 · 2024: 122 · 2023: 116 · 2022: 119 · 2021: 156 · 2020: 117 · 2019: 116 · 2018: 99 · 2017: 101 · 2016: 53
- FWCI
- 37.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Keywords
- 5-fluorouracil, leucovorin, metastatic pancreatic ductal adenocarcinoma, gemcitabine-refractory disease, combination chemotherapy, overall survival, first-line therapy, NAPOLI-1 trial, albumin, Karnofsky performance status
- MeSH terms
- Irinotecan, Gemcitabine, Aged, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Deoxycytidine, Diarrhea, Fatigue, Female, Fluorouracil, Humans, Liposomes, Male, Middle Aged, Neoplasm Metastasis, Neutropenia, Pancreatic Neoplasms, Vomiting, Treatment Outcome, Carcinoma, Pancreatic Ductal, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
